Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case ...

We propose strongly unrealistic data augmentation to improve the robustness of convolutional neural networks (CNNs) for automatic classification of dopamine transporter SPECT against the variability ...

Prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of multiple solid tumors, including renal cell carcinoma (RCC). Studies have demonstrated promising results on the utility ...

You don’t understand anything until you learn it more than one way. —Marvin Minsky (1927–2016) Living organisms maintain homeostasis through dynamic multiorgan systemic interactions (1). Considerable ...

Accurate quantification in emission tomography is essential for internal radiopharmaceutical therapy dosimetry. Mean activity concentration measurements in objects with diameters less than 10 times ...

We introduce a unique bioanalytic hybrid system for the preclinical assessment of radiotracer candidates, combining a 3-dimensional cell culture on an artificial extracellular matrix functioning as a ...

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine MIRD Pamphlet No. 28, Part ...

Natural killer (NK) cells can kill cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC): a tumor-associated IgG antibody binds to the Fcγ receptor CD16 on NK cells via the antibody Fc ...

Despite well-documented limitations, current guidelines recommend the use of size-based RECIST 1.1 for response assessment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) under ...

Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has shown encouraging results for treatment of metastatic castration-resistant prostate cancer (mCRPC) in the prospective, ...

Abstract [177 Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). [177 Lu]Lu-PSMA SPECT/CT 24 h after injection has ...

The use of PET/CT with gastrin-releasing peptide receptor (GRPR) ligand [68Ga]Ga-AMTG has recently been shown to diagnose metastatic disease not detected by 18F-PSMA PET/CT in patients with metastatic ...